French biotech Inventiva’s layoffs and pipeline shift are expected to help keep the company operational into the second half ...

A phase 3 trial of lanifibranor, a pan-PPAR agonist, in patients with MASH and liver fibrosis is ongoing. But with the 96.6 ...

Sarcomatrix Therapeutics, Corp Logo Company Prepares for Phase 1 Clinical Trials of Lead Candidate S-969 in 2025 Our robust preclin ...